In surprise move, FDA delays decision on Lilly’s Alzheimer’s drug, will convene advisory committee
The FDA has pushed back its decision on Eli Lilly’s highly anticipated Alzheimer’s drug donanemab and plans to convene an advisory committee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
